Hutchison China MediTech Ltd - Hong Kong-based biopharmaceutical company - Receives scientific advice from European Medicines Agency's Committee for Medicinal Products for Human Use, for surufatnib for the treatment of patients with advanced neuroendocrine tumours. Based on advice, group concludes that completed studies on tumours both pancreatic and non-pancreatic, along with existing data, could form the basis for supporting a marketing authorisation application. Submission is planned for 2021, following submission to the US Food & Drug Administration.
Current stock price: 455.00 pence
Year-to-date change: up 20%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)